Work

Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia.

Year: 2026
Type: article
Abstract: TO THE EDITOR: Covalent Bruton tyrosine kinase inhibitors (cBTKis) are commonly used targeted agents in early lines of therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); however, treatment following disease progression on cBTKis remains a challenge in clinical practice. Venetoclax is a B-cell lymphoma-2 inhibitor approved for CLL and SLL treatment, either as continuous monotherapy or as a fixed-treatment duration (FTD) regimen in combination with anti-CD20 antibodies (FTD Ven+anti-CD20; frontline, 12 months; relapsed/refractory, 24 months). Venetoclax has demonstrated durable responses and outcomes among patients with previous cBTKi exposure, both in clinical trials (eg, M14 032 and VENICE-1)6,7 and in real-world studies.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: green
OpenAlex ID: W7234838860
FWCI:
Cites:
Cited by:
Related to: 10